[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. 1979

M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
May 1979, Wiener klinische Wochenschrift,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
December 1972, Minerva medica,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
December 1977, Journal of neurology, neurosurgery, and psychiatry,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
January 1972, Zeitschrift fur Neurologie,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
January 1972, Zeitschrift fur Neurologie,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
January 1974, Rivista di neurologia,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
March 1973, Archiv fur Psychiatrie und Nervenkrankheiten,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
November 1973, Die Medizinische Welt,
M Yokochi, and T Kondo, and K Hirayama, and H Narabayashi, and I Kuruma
November 1975, Psychopharmacologia,
Copied contents to your clipboard!